Peripheral Arterial Clinical Trial Analysis 2025: 22+ Emerging Therapies, Novel Mechanisms, and Regenerative Strategies Redefining Vascular Care | DelveInsight

DelveInsight's "Peripheral Arterial Disease - Pipeline Insight, 2025" explores over 22+ therapies in development for peripheral arterial disease (PAD), a chronic and progressive condition caused by atherosclerotic narrowing of arteries that supply blood to the limbs. Despite lifestyle modifications, antiplatelet drugs, and revascularization procedures being the current standards, a large proportion of patients continue to face critical limb ischemia, amputation risks, and poor long-term outcomes-highlighting the need for innovation in the peripheral arterial disease treatment market.

The pipeline is expanding with novel antithrombotic agents, lipid-lowering drugs, and anti-inflammatory therapies that target underlying vascular pathology. Regenerative medicine approaches, including stem cell therapies and angiogenic growth factors, are showing promise in restoring blood flow and tissue perfusion in patients with critical limb ischemia. In addition, RNA-based therapies and gene-modulating approaches are being investigated to improve vascular repair and endothelial function.

With peripheral arterial disease clinical trials spanning biologics, small molecules, and cell-based therapies, the treatment paradigm is shifting toward disease modification rather than symptom management. As late-stage candidates advance, the PAD market is poised for meaningful transformation, offering patients safer, more effective, and potentially limb-saving options.

Interested in learning more about the current treatment landscape and the key drivers shaping the Peripheral Arterial Disease pipeline? Click here: https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Peripheral Arterial Disease Pipeline Report
• DelveInsight's Peripheral Arterial clinical trial analysis depicts a strong space with 20+ active players working to develop 22+ pipeline drugs for Peripheral Arterial Disease treatment.
• The leading Peripheral Arterial Disease companies include AdvancedCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics, IsomAb, and others, who are evaluating their lead assets to improve the Peripheral Arterial Disease treatment landscape.
• Key Peripheral Arterial Disease pipeline therapies in various stages of development include Revacept, Semaglutide, ACP 01, VM202, APAC, VS 367, ISM-001, and others.
• In May 2025, Reflow Medical announced FDA granted De Novo clearance for its Spur Peripheral Retrievable Stent System, designed to treat de novo or restenotic lesions after predilatation in patients with infrapopliteal arterial disease.
• In November 2024, U.S.-based R3 Vascular received investigational device exemption (IDE) approval from the FDA to initiate the pivotal ELITE-BTK trial, aimed at evaluating its bioabsorbable scaffold treatment for peripheral arterial disease (PAD). This trial represents a significant step forward for R3 Vascular in developing innovative therapies for PAD patients.

Request a sample and discover the recent breakthroughs happening in the Peripheral Arterial Disease pipeline landscape at https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Arterial Disease Overview
Peripheral Arterial Disease (PAD) is a common circulatory condition in which narrowed arteries reduce blood flow to the limbs, typically the legs. This reduced blood flow is usually caused by atherosclerosis-the buildup of fatty deposits on the arterial walls-which limits oxygen and nutrient delivery to muscles and tissues. PAD often leads to symptoms such as leg pain or cramping during walking (claudication), numbness, and, in severe cases, non-healing wounds or tissue death.

Risk factors for PAD include smoking, diabetes, hypertension, high cholesterol, and advanced age. Diagnosis is made through physical examination, ankle-brachial index (ABI) testing, and imaging studies. Treatment focuses on lifestyle changes like smoking cessation and exercise, medications to improve blood flow and manage symptoms, and, in advanced cases, surgical interventions such as angioplasty or bypass surgery. Early detection and management are critical to prevent complications like limb ischemia and cardiovascular events.

Find out more about Peripheral Arterial Disease medication at https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Arterial Disease Treatment Analysis: Drug Profile
Semaglutide (Novo Nordisk):
Semaglutide is a long-acting oral GLP-1 analogue developed by Novo Nordisk. It is currently in Phase III clinical trials for the treatment of Peripheral Artery Disease (PAD).

ACP-01 (Hemostemix):
ACP-01 is an autologous cell therapy using a patient's own angiogenic cell precursors (ACPs) to regenerate damaged tissues in critical limb ischemia (CLI) and other vascular diseases. By promoting new blood vessel growth, ACP-01 aims to restore circulation and reduce the risk of amputation. It has received orphan drug designation from the FDA and is currently in Phase II development for PAD.

Revacept (AdvanceCor):
Revacept is a novel Fc-fusion protein designed to bind to damaged blood vessel walls via its GPVI component, acting as a vascular patch to prevent arterial thrombus formation. It is being evaluated in Phase I clinical trials for patients with Peripheral Artery Disease.

Learn more about the novel and emerging Peripheral Arterial Disease pipeline therapies at https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral Arterial Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Peripheral Arterial Disease Pipeline Report
• Coverage: Global
• Key Peripheral Arterial Disease Companies: AdvancedCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics, IsomAb, and others.
• Key Peripheral Arterial Disease Pipeline Therapies: Revacept, Semaglutide, ACP 01, VM202, APAC, VS 367, ISM-001, and others.

To dive deep into rich insights for drugs used for Peripheral Arterial Disease treatment, visit: https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Peripheral Arterial Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Peripheral Arterial Disease Pipeline Therapeutics
6. Peripheral Arterial Disease Pipeline: Late-Stage Products (Phase III)
7. Peripheral Arterial Disease Pipeline: Mid-Stage Products (Phase II)
8. Peripheral Arterial Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.